期刊文献+

一例脑腱黄瘤病患者的CYP27A1基因突变 被引量:8

Mutation analysis of CYP27A1 gene in a patient with cerebrotendinous xanthomatosis
下载PDF
导出
摘要 目的对1例散发脑腱黄瘤病患者的致病基因CYP27A1进行突变鉴定。方法收集患者及父母的外周血,提取基因组DNA,采用PCR扩增CYP27A1基因的所有外显子及剪切位点序列,对PCR产物进行Sanger测序,同时对新发现的突变在105名正常对照中进行测序,以排除多态性位点。结果患者的CYP27A1基因第2内含子发现1个剪切位点突变c.446+1G>T;第5外显子检测到2个错义突变:c.877A>T(p.Met293Leu)及c.1016C>T(p.Thr339Met)。经测序验证,c.446+1G>T及c.877A>T(p.Met293Leu)来源于母亲,为国内外尚未报道的新突变,c.1016C>T(p.Thr339Met)遗传自父亲,为一已知突变。结论发现CYP27A1基因中2个新突变c.446+1G>T、c.877A>T及1个已报道的突变c.1016C>T,这一发现丰富了CYP27A1基因突变谱,为阐明脑腱黄瘤病的发病机制提供新的数据。 Objective To investigate the causative mutations of CYP27A1 gene in a sporadic cerebrotendinous xanthomatosis patient. Methods Genomic DNA was extracted from peripheral blood of the patient and her parents. All exons and splice sites of CYP27A1 gene were amplified by polymerase chain reaction (PCR) followed by Sanger sequenc-ing. 105 healthy unrelated subjects were also sequenced for the novel mutation in CYP27A1. Results A novel splice site mutation c.446+lG〉T, a novel missense mutation c.877A〉T(p.Met293Leu) and a known missense mutation c.1016C〉T (p.Thr339Met) of CYP27A1 gene were identified in the patient. The mother carriers the two novel mutations and the fa-ther the c.1016C〉T(p.Thr339Met) mutation. The two novel mutations were absent in 105 control subjects, respectively. Conclusions Our study detected two novel mutations, c.446 + 1G〉T and c.877A〉T, as well as a known mutation c.1016C〉T, of CYP27A1 in a sporadic cerebrotendinous xanthomatosis patient. Our data provide novel information for the mutational spectrum of the gene, which is applicable in the genetic testing and diagnosis. The data also provide in-sight into the pathogenesis of the disease.
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2014年第1期2-6,共5页 Chinese Journal of Nervous and Mental Diseases
基金 国家自然科学基金(编号:81171070)
关键词 脑腱黄瘤病 CYP27A1基因 突变 Cerebrotendinous xanthomatosis CYP27A1 gene Mutation
  • 相关文献

参考文献12

  • 1Cali JJ, Hsieh CL, Francke U, et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebroten- dinous xanthomatosis[J]. J Biol Chem, 1991, 266(12): 7779-7783.
  • 2Gallus GN, Dotti MT, Federico A. Clinical and molecular diagno- sis of cerebrotendinous xanthomatosis with a review of the muta- tions in the CYP27A1 gene[J]. Neurol Sci, 2006, 27(2): 143-149.
  • 3Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendi- nous xanthomatosis[J]. Brain, 2000, 123 (Pt 5): 908-919.
  • 4Pilo-De-La-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Ce- rebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey[J]. Eur J Neurol, 2011, 18(10): 1203-1211.
  • 5魏博,毛善英,刘志蓉,丁美萍.脑腱性黄色瘤病的临床特征与基因突变分析[J].中华神经科杂志,2012,45(9):646-649. 被引量:11
  • 6Ginanneschi F, Mignarri A, Mondelli M, et al. Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid[J]. J Neurol, 2013, 260(1): 268-274.
  • 7Verrips A, van Engelen BG, Wevers RA, et al. Presence of diar- rhea and absence of tendon xanthomas in patients with cerebro- tendinous xanthomatosis[J]. Arch Neurol, 2000, 57(4): 520-524.
  • 8Gallus GN, Dotti MT, Mignarri A, et al. Four novel CYP27A1 mutations in seven Italian patients with CTX[J]. Eur J Neurol, 2010, 17(10): 1259-1262.
  • 9Yahalom G, Tsabari R, Molshatzki N, et al. Neurological out- come in cerebrotendinous xanthomatosis treated with chenode- oxycholic acid: early versus late diagnosis[J]. Clin Neuropharma- col, 2013, 36(3): 78-83.
  • 10Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and ju- venile cataracts: think eerebrotendinous xanthomatosis and treat [J]. Pediatrics, 2009, 123(1): 143-147.

二级参考文献17

  • 1Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain : clinical, prognostic, and genetic survey. Eur J Neurol, 2011,18 : 1203-1211.
  • 2Rafiq M, Sharrack N, Shaw P J, et al. A neurological rarity not to be missed : cerebrotendinous xanthomatosis. Pract Neurol, 2011, 11:296-300.
  • 3Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci,2006.27: 143-149.
  • 4Moghadasian MH. Cerebrotendinous xanthomatosis : clinical course, genotypes and metabolic backgrounds. Clin Invest Med, 2004,27 : 42-50.
  • 5Fillppi J, Irarr6zaval S, Peredo P, et al. Cerebrotendinous xanthomatosis report of one case. Rev M6d Chile,2009,137: 815- 820.
  • 6Okuma H, Kitagawa Y, Tokuoka K, et al. Cerebrotendinous Xanthomatosis with cerebellar ataxia as the chief symptom. Intern Med ,2007,46 : 1259-1261.
  • 7Grandas F, Martin-Moro M, Garcia-Munozguren S, et al. Early- onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord,2002,17 : 1396-1397.
  • 8Pilo B, de Blas G, Sobrido M J, et al. Neurophysiological study in cerebrotendinous xanthomatosis. Muscle Nerve, 2011,43 : 531- 536.
  • 9Pilo-de-la-Fuente B, Sobrido MJ, Giros M, et al. Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis. Neurologia,2011,26 :397-404.
  • 10Naqi S, Bouchriha M, Sehai R, et al. Imaging of cerehrotendinous xanthomatosis. J Radio1,2006,87 : 1883-1886.

共引文献10

同被引文献48

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部